Neurogene
NGNE
43 hedge funds and large institutions have $300M invested in Neurogene in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 4
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more funds holding
Funds holding: 40 → 43 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.26% less ownership
Funds ownership: 4.77% → 4.51% (-0.26%)
4% less capital invested
Capital invested by funds: $314M → $300M (-$13.8M)
93% less call options, than puts
Call options by funds: $31K | Put options by funds: $427K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.59M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$1.44M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.14M |
| 4 |
BlackRock
New York
|
+$356K |
| 5 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$301K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.6M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$3.05M |
| 3 |
NC
Nexthera Capital
New York
|
-$1.28M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$704K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$329K |
NGNE Hedge Fund Activity: Q3 2017 in Review
43 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2017, worth a combined $300M — down 4.4% from $314M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new NGNE positions and 5 closed out — a net gain of 3 holders — while 20 added to existing stakes and 4 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $3.59M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.6M sold.
- 43 institutional investors held Neurogene (NGNE) as of Q3 2017, up from 40 in Q2 2017.
- Funds reported $300M of Neurogene stock for Q3 2017, down 4.4% quarter-over-quarter.
- 8 funds opened new Neurogene positions in Q3 2017 and 5 closed out, a net change of +3 holders.
- The largest Neurogene buyer in Q3 2017 was Adage Capital Partners, an estimated $3.59M added.
- The largest Neurogene seller in Q3 2017 was RA Capital Management, an estimated $19.6M sold.
Based on aggregated 13F filings for Q3 2017.